×

CellRapeutics™ Serum from Alzheimer's Disease Donor (XS-0426-XU22)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Harvested from donors with clinical AD, this serum is processed to preserve delicate neuro-inflammatory markers and amyloid-associated proteins. It facilitates research into systemic biomarkers of neurodegeneration and the peripheral immune system's role in the progression of cognitive decline.

Specific Inquiry

  • Size:
  Add to Cart

Donor Information

  • Product Name
  • CellRapeutics™ Serum from Alzheimer's Disease Donor
  • Cat. No.
  • XS-0426-XU22
  • Donor Age
  • Senior
  • Donor Health
  • Clinically diagnosed with Alzheimer's Disease. Serum contains neuro-associated metabolic markers and systemic inflammatory signatures that reflect chronic neurodegenerative processes and blood-brain barrier permeability changes.
  • Ethnicity
  • Diverse backgrounds available.
  • Anticoagulant
  • None (separated via centrifugation following natural coagulation).
  • Additional Donor Information
  • Each lot features serum from donors with clinically diagnosed Alzheimer's. Profiles include cognitive assessment scores, disease stage, and available neuro-inflammatory or amyloid-related biomarker history.
  • Clinical Profile
  • Cognitive assessment scores, disease stage, and relevant neurological imaging findings.

Additional Information

  • Medication History
  • Available upon request. Records of Cholinesterase inhibitors, NMDA receptor antagonists, and any anti-amyloid monoclonal antibody treatments.
  • Formulation
  • Frozen
  • Cell Viability
  • Cell-free (no residual erythrocytes or leukocytes).
  • Mycoplasma Testing
  • Negative
  • Sterility Testing
  • Negative
  • Application
  • Drug Discovery, Immuno-oncology Research
  • Research Use Only
  • RUO
  • Quality Control
  • Each serum batch undergoes rigorous IRB-compliant screening, ensuring pathogen-free safety, consistent physicochemical properties, and standardized clinical characterization of disease-specific biomarkers to provide a reliable, high-purity biological matrix.
  • Storage
  • Store at -80°C or below for long-term stability, or at -20°C for up to 6 months, avoid repeated freeze-thaw cycles to preserve product quality.
  • Shiping
  • Dry Ice
  • Handling Notes
  • Thaw slowly on ice or at 4°C and centrifuge to remove cryoprecipitates, immediate aliquoting upon first thaw is recommended to maintain autoantibody functional integrity.
  • Warnings
  • Treat as potentially biohazardous human-derived material and handle strictly under BSL-2 guidelines using appropriate personal protective equipment.
  • Size
  • 1ML
  • Keywords
  • CellRapeutics™ Serum from Alzheimer's Disease Donor, Serum, Alzheimer's Disease

Case Studies

Customer Reviews and Q&As

There are currently no customer reviews or questions for CellRapeutics™ Serum from Alzheimer's Disease Donor (XS-0426-XU22). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.